Compare HLMN & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLMN | KARD |
|---|---|---|
| Founded | 1964 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2020 | 2026 |
| Metric | HLMN | KARD |
|---|---|---|
| Price | $7.17 | $16.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.60 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 413.4K |
| Earning Date | 04-27-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.22 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,552,224,000.00 | N/A |
| Revenue This Year | $7.65 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $89.44 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $6.92 | $15.86 |
| 52 Week High | $10.85 | $27.00 |
| Indicator | HLMN | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 36.63 | 34.78 |
| Support Level | $6.98 | N/A |
| Resistance Level | $8.56 | $22.81 |
| Average True Range (ATR) | 0.26 | 1.60 |
| MACD | -0.01 | -0.36 |
| Stochastic Oscillator | 29.82 | 13.76 |
Hillman Solutions Corp is a provider of hardware-related products and related merchandising services to retail markets in North America. The company sells its products to hardware stores, home centers, mass merchants, pet supply stores, and other retail outlets. Its product lines include thousands of small parts such as fasteners and related hardware items; threaded rod and metal shapes; keys and accessories; builder's hardware; personal protective equipment, such as gloves and eye-wear; and identification items, such as tags and letters, numbers, and signs. The segments of the company are Hardware and Protective Solutions, which is the key revenue-generating segment; Robotics and Digital Solutions; and Canada. It has a business presence in the U.S, Canada and Mexico.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.